On Monday, the Scottish Medicines Consortium (SMC) updated its advice on the use of the combination direct acting antiviral, ledipasvir/sofosbuvir (Harvoni).
Previously advice has restricted ledipasvir/sofosbuvir for use in genotype 1 and 4; this now extends advice to include use in genotype 3.
Haemophilia Scotland made a patient group submission in support of this change. Although it is very welcome, it doesn’t change the fact that genotype 3 remains the most difficult genotype to treat with the new therapies.
